Compare Novavax Inc (NVAX) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Zoom Video Communications, Inc. — how do they compare? Novavax Inc trades at $9.9 (market cap $1.68B), while Zoom Video Communications, Inc. trades at $96.82 (market cap $28.14B). The key difference: Zoom Video Communications, Inc. is far larger — about 16.8× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Zoom Video Communications, Inc. nearer its low. Which is the better fit depends on your goals.
| NVAX | ZM | |
|---|---|---|
Market Cap | $1.68B | $28.14B |
Sector | Health | Technology |
52-Week High | $11.19 | $111.88 |
52-Week Low | $6.22 | $72.72 |
Enterprise Value | $1.26B | $20.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
Zoom (ZM) trades at $96.44, down 4.83% on the day, amid a bearish technical signal and soft Q3 profit guidance that overshadowed a Q2 earnings beat. The stock shows strong fundamentals with a P/E of 8.95, net income margin of 65.19%, and positive cash flow trends, but faces near-term pressure from investor concerns over growth outlook. Recent board appointments and enterprise revenue strength provide some optimism.
The outlook is mixed; solid profitability and low valuation offer upside potential toward the $119.63 consensus price target, but risks include competitive pressures and execution on guidance. Analyst sentiment is cautious with 55.1% hold ratings, reflecting uncertainty around future growth catalysts versus current operational resilience.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
